Association of HLA Typing and Alloimmunity With Posttransplantation Membranous Nephropathy: A Multicenter Case Series

Published:April 28, 2020DOI:

      Rationale & Objectives

      Posttransplantation membranous nephropathy (MN) represents a rare complication of kidney transplantation that can be classified as recurrent or de novo. The clinical, pathologic, and immunogenetic characteristics of posttransplantation MN and the differences between de novo and recurrent MN are not well understood.

      Study Design

      Multicenter case series.

      Setting & Participants

      We included 77 patients from 5 North American and European medical centers with post–kidney transplantation MN (27 de novo and 50 recurrent). Patients with MN in the native kidney who received kidney allografts but did not develop recurrent MN were used as nonrecurrent controls (n = 43). To improve understanding of posttransplantation MN, we compared de novo MN with recurrent MN and then contrasted recurrent MN with nonrecurrent controls.


      Compared with recurrent MN, de novo MN was less likely to be classified as primary MN (OR, 0.04; P < 0.001) and had more concurrent antibody-mediated rejection (OR, 12.0; P < 0.001) and inferior allograft survival (HR for allograft failure, 3.2; P = 0.007). HLA-DQ2 and HLA-DR17 antigens were more common in recipients with recurrent MN compared with those with de novo MN; however, the frequency of these recipient antigens in recurrent MN was similar to that in nonrecurrent MN controls. Among the 93 kidney transplant recipients with native kidney failure attributed to MN, older recipient age (HR per each year older, 1.03; P = 0.02), recipient HLA-A3 antigen (HR, 2.5; P = 0.003), steroid-free immunosuppressive regimens (HR, 2.84; P < 0.001), and living related allograft (HR, 1.94; P = 0.03) were predictors of MN recurrence.


      Retrospective case series, limited sample size due to rarity of the disease, nonstandardized nature of data collection and biopsies.


      De novo and recurrent MN likely represent separate diseases. De novo MN is associated with humoral alloimmunity and guarded outcome. Potential predisposing factors for recurrent MN include recipients who are older, recipient HLA-A3 antigen, steroid-free immunosuppressive regimen, and living related donor kidney.

      Index Words

      To read this article in full you will need to make a payment


      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ronco P.
        • Debiec H.
        Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization.
        J Am Soc Nephrol. 2005; 16: 1205-1213
        • Glassock R.J.
        Secondary membranous glomerulonephritis.
        Nephrol Dial Transplant. 1992; 7: 64-71
        • Beck Jr., L.H.
        • Bonegio R.G.
        • Lambeau G.
        • et al.
        M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.
        N Engl J Med. 2009; 361: 11-21
        • Klouda P.T.
        • Manos J.
        • Acheson E.J.
        • et al.
        Strong association between idiopathic membranous nephropathy and HLA-DRW3.
        Lancet. 1979; 2: 770-771
        • Vaughan R.W.
        • Demaine A.G.
        • Welsh K.I.
        A DQA1 allele is strongly associated with idiopathic membranous nephropathy.
        Tissue Antigens. 1989; 34: 261-269
        • Vaughan R.W.
        • Tighe M.R.
        • Boki K.
        • et al.
        An analysis of HLA class II gene polymorphism in British and Greek idiopathic membranous nephropathy patients.
        Eur J Immunogenet. 1995; 22: 179-186
        • Stanescu H.C.
        • Arcos-Burgos M.
        • Medlar A.
        • et al.
        Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy.
        N Engl J Med. 2011; 364: 616-626
        • van de Logt A.E.
        • Fresquet M.
        • Wetzels J.F.
        • Brenchley P.
        The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery.
        Kidney Int. 2019; 96: 1292-1302
        • Cosyns J.P.
        • Couchoud C.
        • Pouteil-Noble C.
        • Squifflet J.P.
        • Pirson Y.
        Recurrence of membranous nephropathy after renal transplantation: probability, outcome and risk factors.
        Clin Nephrol. 1998; 50: 144-153
        • El-Zoghby Z.M.
        • Grande J.P.
        • Fraile M.G.
        • Norby S.M.
        • Fervenza F.C.
        • Cosio F.G.
        Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies.
        Am J Transplant. 2009; 9: 2800-2807
        • Pippias M.
        • Stel V.S.
        • Areste-Fosalba N.
        • et al.
        Long-term kidney transplant outcomes in primary glomerulonephritis: analysis from the ERA-EDTA Registry.
        Transplantation. 2016; 100: 1955-1962
        • Pruthi R.
        • McClure M.
        • Casula A.
        • et al.
        Long-term graft outcomes and patient survival are lower posttransplant in patients with a primary renal diagnosis of glomerulonephritis.
        Kidney Int. 2016; 89: 918-926
        • Truong L.
        • Gelfand J.
        • D'Agati V.
        • et al.
        De novo membranous glomerulonephropathy in renal allografts: a report of ten cases and review of the literature.
        Am J Kidney Dis. 1989; 14: 131-144
        • Berger B.E.
        • Vincenti F.
        • Biava C.
        • Amend Jr., W.J.
        • Feduska N.
        • Salvatierra Jr., O.
        De novo and recurrent membranous glomerulopathy following kidney transplantation.
        Transplantation. 1983; 35: 315-319
        • Couchoud C.
        • Pouteil-Noble C.
        • Colon S.
        • Touraine J.L.
        Recurrence of membranous nephropathy after renal transplantation. Incidence and risk factors in 1614 patients.
        Transplantation. 1995; 59: 1275-1279
        • Honda K.
        • Horita S.
        • Toki D.
        • et al.
        De novo membranous nephropathy and antibody-mediated rejection in transplanted kidney.
        Clin Transplant. 2011; 25: 191-200
        • Wen J.
        • Xie K.
        • Zhang M.
        • et al.
        HLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy.
        Medicine (Baltimore). 2016; 95: e4809
        • Quintana L.F.
        • Blasco M.
        • Seras M.
        • et al.
        Antiphospholipase A2 receptor antibody levels predict the risk of posttransplantation recurrence of membranous nephropathy.
        Transplantation. 2015; 99: 1709-1714
        • Andrésdóttir M.B.
        • Wetzels J.F.
        Increased risk of recurrence of membranous nephropathy after related donor kidney transplantation.
        Am J Transplant. 2012; 12: 265-266
        • Karhus L.L.
        • Thuesen B.H.
        • Skaaby T.
        • Rumessen J.J.
        • Linneberg A.
        The distribution of HLA DQ2 and DQ8 haplotypes and their association with health indicators in a general Danish population.
        United Eur Gastroenterol J. 2018; 6: 866-878
        • Cummins A.G.
        • Roberts-Thomson I.C.
        Prevalence of celiac disease in the Asia-Pacific region.
        J Gastroenterol Hepatol. 2009; 24: 1347-1351
        • Tjernstrom F.
        • Hellmer G.
        • Nived O.
        • Truedsson L.
        • Sturfelt G.
        Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN∗2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus.
        Lupus. 1999; 8: 103-108
        • Edwards C.Q.
        • Griffen L.M.
        • Kushner J.P.
        Increased frequency of HLA-A3 in subjects with sporadic porphyria cutanea tarda.
        Tissue Antigens. 1988; 31: 250-253
        • Fogdell-Hahn A.
        • Ligers A.
        • Gronning M.
        • Hillert J.
        • Olerup O.
        Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease.
        Tissue Antigens. 2000; 55: 140-148
        • Posthuma E.F.
        • Falkenburg J.H.
        • Apperley J.F.
        • et al.
        HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.
        Blood. 1999; 93: 3863-3865
        • Loupy A.
        • Haas M.
        • Solez K.
        • et al.
        The Banff 2015 Kidney Meeting Report: current challenges in rejection classification and prospects for adopting molecular pathology.
        Am J Transplant. 2017; 17: 28-41
        • Racusen L.C.
        • Solez K.
        • Colvin R.B.
        • et al.
        The Banff 97 working classification of renal allograft pathology.
        Kidney Int. 1999; 55: 713-723
        • Haas M.
        • Loupy A.
        • Lefaucheur C.
        • et al.
        The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.
        Am J Transplant. 2018; 18: 293-307
        • Larsen C.P.
        • Walker P.D.
        Phospholipase A2 receptor (PLA2R) staining is useful in the determination of de novo versus recurrent membranous glomerulopathy.
        Transplantation. 2013; 95: 1259-1262
        • Morales J.M.
        • Pascual-Capdevila J.
        • Campistol J.M.
        • et al.
        Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients.
        Transplantation. 1997; 63: 1634-1639
        • Cruzado J.M.
        • Carrera M.
        • Torras J.
        • Grinyo J.M.
        Hepatitis C virus infection and de novo glomerular lesions in renal allografts.
        Am J Transplant. 2001; 1: 171-178
        • Debiec H.
        • Guigonis V.
        • Mougenot B.
        • et al.
        Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies.
        N Engl J Med. 2002; 346: 2053-2060
        • Byrne-Dugan C.J.
        • Collins A.B.
        • Lam A.Q.
        • Batal I.
        Membranous nephropathy as a manifestation of graft-versus-host disease: association with HLA antigen typing, phospholipase A2 receptor, and C4d.
        Am J Kidney Dis. 2014; 64: 987-993
        • Reddy P.
        • Johnson K.
        • Uberti J.P.
        • et al.
        Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
        Bone Marrow Transplant. 2006; 38: 351-357
        • Charpentier B.
        • Levy M.
        [Cooperative study of de novo extramembranous glomerulonephritis in renal allografts in humans: report of 19 new cases in 1550 renal transplant patients of the transplantation group of the Ile de France].
        Nephrologie. 1982; 3: 158-166
        • Schwarz A.
        • Krause P.H.
        • Offermann G.
        • Keller F.
        Impact of de novo membranous glomerulonephritis on the clinical course after kidney transplantation.
        Transplantation. 1994; 58: 650-654
        • Antignac C.
        • Hinglais N.
        • Gubler M.C.
        • Gagnadoux M.F.
        • Broyer M.
        • Habib R.
        De novo membranous glomerulonephritis in renal allografts in children.
        Clin Nephrol. 1988; 30: 1-7
        • McGrogan A.
        • Franssen C.F.
        • de Vries C.S.
        The incidence of primary glomerulonephritis worldwide: a systematic review of the literature.
        Nephrol Dial Transplant. 2011; 26: 414-430
        • Debiec H.
        • Martin L.
        • Jouanneau C.
        • et al.
        Autoantibodies specific for the phospholipase A2 receptor in recurrent and de novo membranous nephropathy.
        Am J Transplant. 2011; 11: 2144-2152
        • Allen P.J.
        • Chadban S.J.
        • Craig J.C.
        • et al.
        Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes.
        Kidney Int. 2017; 92: 461-469
        • Grupper A.
        • Cornell L.D.
        • Fervenza F.C.
        • Beck Jr., L.H.
        • Lorenz E.
        • Cosio F.G.
        Recurrent membranous nephropathy after kidney transplantation: treatment and long-term implications.
        Transplantation. 2016; 100: 2710-2716
        • Kattah A.
        • Ayalon R.
        • Beck Jr., L.H.
        • et al.
        Anti-phospholipase A(2) receptor antibodies in recurrent membranous nephropathy.
        Am J Transplant. 2015; 15: 1349-1359
        • Agarwal S.K.
        • Dash S.C.
        • Mehta S.N.
        • Bhuyan U.N.
        Recurrence of idiopathic membranous nephropathy in HLA-identical allograft.
        Nephron. 1992; 60: 366
        • Kennard A.L.
        • Jiang S.H.
        • Walters G.D.
        Increased glomerulonephritis recurrence after living related donation.
        BMC Nephrol. 2017; 18: 25
        • Cosio F.G.
        • Cattran D.C.
        Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation.
        Kidney Int. 2017; 91: 304-314
        • Gupta G.
        • Fattah H.
        • Ayalon R.
        • et al.
        Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation.
        Clin Transplant. 2016; 30: 461-469
        • Saito T.
        • Yusa A.
        • Soma J.
        • Ootaka T.
        • Sato H.
        • Ito S.
        Significance of leukocyte infiltration in membranous nephropathy with segmental glomerulosclerosis.
        Nephron. 1998; 80: 414-420